

Supplemental Table 1. Time to First Exacerbation in Days Stratified by Baseline Characteristic

<b>Baseline Characteristic</b>	<b>PLACEBO</b> N=74 days (CI <sub>95%</sub> )	<b>RESCUE</b> N=71 days (CI <sub>95%</sub> )	<b>DAILY</b> N=72 days (CI <sub>95%</sub> )	<b>COMBINED</b> N=71 days (CI <sub>95%</sub> )
All Subjects	84 (28,121)	102 (59,137)	109 (49,241)	134 (90,244)
Male	54 (21,124)	108 (55,161)	146 (100,254)	91 (17,189)
Female	92 (26,136)	95 (25,138)	57 (11,291)	184 (93,259)
Age 6-11 years	80 (28,123)	102 (55,127)	137 (49,265)	165 (90,260)
Age 12-18 years	88 (7,125)	110 (29,277)	76 (14,241)	95 (1,247)
White	92 (43,123)	108 (55,137)	136 (49,254)	156 (90,247)
Non-White	28 (14,136)	84 (53,298)	62 (11,123)	93 (1,269)
Hispanic or Latino	88 (21,153)	84 (28,127)	90 (44,245)	134 (90,269)
Non-Hispanic or Latino	80 (32,110)	112 (63,255)	117 (35,254)	139 (18,247)
Diagnosed ≤3 years	80 (24,121)	63 (29,255)	108 (14,241)	187 (92,260)
Diagnosed > 3 years	88 (22,153)	108 (82,127)	169 (35,291)	92 (18,244)
Parental asthma	108 (43,137)	102 (59,137)	100 (14,254)	216 (90,269)
No parental asthma	28 (14,97)	106 (53,255)	116 (44,265)	96 (18,189)
Eczema	45 (24,105)	88 (29,255)	169 (69,291)	99 (42,247)
No Eczema	97 (32,125)	108 (63,137)	80 (14,254)	166 (55,259)
Skin Test Positive	54 (24,110)	95 (59,137)	108 (33,291)	93 (55,184)
Skin Test Negative	136 (18,222)	199 (112,286)	105 (11,265)	244 (146,269)
IgE < 350 K/μL	96 (43,125)	59 (29,161)	110 (49,254)	156 (91,244)
IgE ≥ 350 K/μL	30 (10,110)	123 (63,255)	72 (14,308)	82 (42,122)
FEV <sub>1</sub> reversibility ≥12%	54 (22,137)	63 (29,161)	59 (11,291)	99 (91,259)
FEV <sub>1</sub> reversibility <12%	92 (32,123)	108 (82,138)	137 (44,254)	146 (55,244)
Methacholine PC <sub>20</sub> ≤12.5 mg/dL	54 (24,105)	86 (55,123)	69 (33,245)	122 (90,244)
Methacholine PC <sub>20</sub> >12.5 mg/dL	124 (26,137)	138 (25,255)	164 (80,291)	166 (42,269)
eNO <25 ppb	96 (32,125)	95 (55,138)	109 (49,241)	122 (91,244)
eNO ≥25 ppb	20 (7,110)	113 (29,255)	35 (35,35)	104 (18,259)
Complete run-in asthma control	105 (54,136)	95 (63,127)	241 (100,265)	175 (93,260)
Incomplete run-in asthma control	26 (13,95)	112 (29,277)	69 (14,169)	67 (1,259)
≥1 oral ICS past year	92 (26,137)	61 (29,286)	69 (11,245)	107 (55,244)
<1 oral ICS past year	54 (21,123)	114 (82,161)	123 (44,254)	175 (18,260)

*IgE*, serum immunoglobulin E; *FEV<sub>1</sub>*, forced expiratory volume in 1 second; *PC<sub>20</sub>*, concentration of methacholine that causes a 20% fall in *FEV<sub>1</sub>*; *eNO*, exhaled nitric oxide.

Supplemental Table 2. Mean Asthma Control Days Stratified by Baseline Characteristic

<b>Baseline Characteristic</b>	<b>PLACEBO (N=74) mean (SD)</b>	<b>RESCUE (N=71) mean (SD)</b>	<b>DAILY (N=72) mean (SD)</b>	<b>COMBINED (N=71) mean (SD)</b>
All Subjects	0.83 (0.18)	0.81 (0.19)	0.89 (0.14)	0.91 (0.15)
Male	0.80 (0.18)	0.79 (0.22)	0.90 (0.13)	0.91 (0.12)
Female	0.87 (0.17)	0.83 (0.15)	0.87 (0.16)	0.91 (0.18)
Age 6-11 years	0.80 (0.19)	0.76 (0.20)	0.87 (0.16)	0.89 (0.17)
Age 12-18 years	0.89 (0.14)	0.91 (0.10)	0.93 (0.09)	0.94 (0.10)
White	0.84 (0.18)	0.82 (0.18)	0.88 (0.14)	0.91 (0.12)
Non-White	0.80 (0.18)	0.79 (0.21)	0.92 (0.14)	0.89 (0.20)
Hispanic or Latino	0.88 (0.12)	0.87 (0.17)	0.91 (0.14)	0.94 (0.09)
Non-Hispanic or Latino	0.80 (0.20)	0.78 (0.19)	0.88 (0.14)	0.89 (0.17)
Eczema	0.80 (0.19)	0.77 (0.20)	0.90 (0.12)	0.89 (0.18)
No Eczema	0.86 (0.16)	0.85 (0.17)	0.88 (0.16)	0.93 (0.11)
Diagnosed ≤3 years	0.82 (0.18)	0.80 (0.17)	0.89 (0.13)	0.88 (0.18)
Diagnosed >3 years	0.84 (0.18)	0.82 (0.20)	0.89 (0.15)	0.94 (0.10)
Parental asthma	0.84 (0.17)	0.80 (0.20)	0.88 (0.15)	0.94 (0.07)
No parental asthma	0.81 (0.20)	0.82 (0.18)	0.91 (0.11)	0.90 (0.13)
Skin Test Positive	0.80 (0.20)	0.79 (0.20)	0.90 (0.13)	0.90 (0.16)
Skin Test Negative	0.91 (0.07)	0.89 (0.13)	0.86 (0.17)	0.93 (0.10)
IgE < 350 K/μL	0.85 (0.17)	0.84 (0.17)	0.87 (0.15)	0.90 (0.17)
IgE ≥ 350 K/μL	0.77 (0.19)	0.77 (0.22)	0.91 (0.13)	0.94 (0.08)
FEV <sub>1</sub> reversibility ≥12%	0.74 (0.21)	0.77 (0.18)	0.85 (0.15)	0.90 (0.14)
FEV <sub>1</sub> reversibility <12%	0.85 (0.16)	0.82 (0.19)	0.90 (0.14)	0.91 (0.15)
Methacholine PC <sub>20</sub> ≤12.5 mg/dL	0.83 (0.18)	0.79 (0.19)	0.88 (0.14)	0.90 (0.17)
Methacholine PC <sub>20</sub> >12.5 mg/dL	0.84 (0.17)	0.86 (0.17)	0.90 (0.14)	0.93 (0.09)
eNO <25 ppb	0.83 (0.18)	0.82 (0.18)	0.89 (0.14)	0.91 (0.15)
eNO ≥25 ppb	0.84 (0.16)	0.81 (0.17)	0.92 (0.07)	0.89 (0.17)
Complete run-in asthma control	0.88 (0.14)	0.81 (0.19)	0.90 (0.15)	0.94 (0.08)
Incomplete run-in control	0.73 (0.21)	0.81 (0.18)	0.88 (0.13)	0.84 (0.21)
≥1 oral ICS past year	0.82 (0.21)	0.76 (0.23)	0.90 (0.07)	0.92 (0.07)
<1 oral ICS past year	0.83 (0.17)	0.84 (0.15)	0.88 (0.16)	0.90 (0.17)

IgE, serum immunoglobulin E; FEV<sub>1</sub>, forced expiratory volume in 1 second; PC<sub>20</sub>, concentration of methacholine that causes a 20% fall in FEV<sub>1</sub>; eNO, exhaled nitric oxide.

Acknowledgments (suggested for on-line supplement):

The members of the CARE Network are as follows:

Clinical Centers:

National Jewish Health, Denver: Stanley J. Szefer, MD (Principal Investigator); Gary Larsen, MD (Co-Investigator); Ronina Covar, MD (Co-Investigator); Marzena E. Krawiec, MD (Co-Investigator); Joseph Spahn, MD (Co-Investigator); D Sundström (Center Coordinator); Lina Escobar (Coordinator); Melanie Gleason, PA-C; Sakari Graves (Coordinator); Phillip López (Coordinator); Katie Patterson (Coordinator); Melanie Phillips (Coordinator); Gayle Spears, PA-C; Michael White (Research Assistant).

We also thank the pediatric allergy/immunology and pulmonary fellows for their participation (Jayna Doshi, MD; Richard Hendershot, MD; Brian Kang, MD; Tracy Kruzick, MD; Jonathan Malka, MD; John Prpich, MD; and Grace Tamesis, MD).

University of Wisconsin, Clinical Science Center, Madison: Robert F. Lemanske, Jr. MD (Principal Investigator); Christine A. Sorkness, PharmD, (Co-Investigator); Mark H. Moss, MD (Co-Investigator); Theresa W. Guilbert, MD (Co-Investigator); Christine Virnig, MD (Allergy Fellow); Dan Jackson, MD (Allergy Fellow); David B. Allen, MD (Consultant); Sarah Garibay, RN (Coordinator); Kelly Miller BS (Coordinator); Holly Eversoll, RN (Coordinator); Kathleen Kelly Shanovich, NP; Rick Kelley (Pulmonary Function Manager); Ryan Burton, MS; Lisa Hurley (Coordinator); Lola Awoyinka; Rachel Crawford (Coordinator); Sheila Turcsanyi (Coordinator); Sarah Sund (Coordinator).

University of California San Diego Medical Center and Kaiser Permanente Allergy Center, San Diego: Robert S. Zeiger, MD, Ph.D. (Principal Investigator); Gregory Heldt, MD (Co-Investigator); Michael H. Mellon, MD (Co-Investigator); Michael Schatz, MD (Co-Investigator); Noah J. Friedman, MD (Co-Investigator); Sandra C. Christiansen, MD (Co-Investigator); Kathleen Harden, RN (Coordinator); Terrie Long, RN (Coordinator); Eva Rodriguez, RRT; Elsa Y. Rodriguez, Travis Macaraeg.

Washington University School of Medicine, St. Louis: Robert C. Strunk, MD (Principal Investigator); Leonard B. Bacharier, MD (Co-Investigator); James M. Corry, MD (Co-Investigator); Katherine Rivera-

Spoljaric, MD (Co-Investigator); Caroline Horner, MD (Co-Investigator); Avraham Beigelman, MD (Co-Investigator); Tina Oliver, CCRP, CRT (Coordinator); Valerie Morgan RRT, CCRP (Coordinator); Kevin Hodgdon, RRT, CPFT (Coordinator); Trisha Washington, CPFT (Coordinator); Wanda Caldwell, RRT, MBA (Coordinator), Debbie Pirrello, RRT-NPS; Cindy Moseid (Secretary).

Arizona Respiratory Center, University of Arizona, College of Medicine, Tucson: Fernando D. Martinez, MD (Principal Investigator); Wayne J. Morgan, MD (Co-Investigator); Mark A. Brown, MD (Co-Investigator); James Goodwin, PhD (Research Manager); Monica Vasquez, MPH, MEd (Coordinator); Rosemary Weese, RN, RRT; Silvia Lopez, RN; Jesus Wences, BS (Research Technician), Elizabeth Beckett Firmage (Administrative Coordinator).

University of New Mexico, Albuquerque: Hengameh H. Raissy, PharmD, PhC (Principal Investigator) William Kelly, PharmD (Principal Investigator); Lea Davies, MD (Co-Investigator); Mary Spicher (Coordinator); Franceska Kelly (Coordinator); Christy Batson.

Milwaukee Clinical Center: Elizabeth Bade, MD (Principal Investigator); Dennis Baumgardner, MD (Co-Investigator); Jennifer Evertsen, MS (Project Manager); Ruth Perez (coordinator); Jennifer Kroll (coordinator); Julie Katrichis (data entry).

#### Resource Centers:

Chair's Office, National Jewish Health, Denver, Colorado: Lynn M. Taussig, MD (Study Chair).

Project Office, National Heart, Lung and Blood Institute, Bethesda, Maryland: James Kiley, PhD, (Director of the NHLBI Division of Lung Diseases); Virginia Taggart, MPH (NHLBI Project Scientist); Gail Weinmann MD (Executive Secretary, DSMB); Gang Zheng, PhD.

Data Coordinating Center, Penn State University College of Medicine, Hershey, Pennsylvania: David Mauger, PhD (Principal Investigator);, Vernon M. Chinchilli PhD, (Co-Investigator); Ian Paul, MD (Co-Investigator); Brenda Phillips, MS (Scientific Coordinator); Georgia Brown, RN, MS (Scientific Coordinator); Nora Graber, MS (Scientific Coordinator); Sue Boehmer, MA (Scientific Coordinator);

Loretta Doty (Project Coordinator); Lindsay Texter; Jim Schmidt; Linda Ferrari; Cathy Goeckel; Sherrie Whisler; Brenda Beers; Judy Potteiger; Sara Marlin; Brett Larsen; Linda Miller; Linda Vignati; Chris Mardekian; Victor Sanchez; Vanessa Simmons.

#### Committees:

Data and Safety Monitoring Board: Thomas F. Boat, MD (Chair), Cincinnati Children's Hospital Medical Center, Cincinnati, OH; William C. Bailey, MD, The University of Alabama at Birmingham, Alabama; Mary Kay Garcia, PhD, RN, CPNP, Coto DeCaza, CA; Carolyn M. Kercksmar, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Lester Lyndon Key, Jr. MD, Medical University of South Carolina, Charleston, SC; James Tonascia, PhD, Johns Hopkins University, Baltimore, MD; Benjamin S. Wilfond, MD, University of Washington School of Medicine, Seattle, WA.

Protocol Review Committee: Philip Ballard, MD, PhD (Chair), University of California San Francisco, San Francisco, CA; Clarence E. Davis, PhD, University of North Carolina, Chapel Hill, NC; Diane E. McLean, MD, PhD, MPH, New York Presbyterian Hospital, New York, NY; Paul O'Byrne, MD, McMaster University, Hamilton, ON; Mark Liu, MD, Johns Hopkins Asthma and Allergy Center, Baltimore, MD; M. Anne Spence, PhD, University of California, Irvine, Irvine, CA; Meyer Kattan, MD, Mount Sinai Medical Center, New York, New York.

Executive Committee: Lynn M. Taussig, MD (Chair); Virginia S. Taggart, MPH; Stanley J. Szeffler, MD; Robert F. Lemanske, Jr., MD; Robert S. Zeiger, MD, PhD; Robert C. Strunk, MD; Fernando D. Martinez, MD; David Mauger, PhD.

Publication and Presentation Committee: Robert F. Lemanske, Jr., MD (Chair); Stanley J. Szeffler, MD; Fernando D. Martinez, MD.

Quality Control Committee: Robert S. Zeiger, MD, PhD, (Chair); Robert C. Strunk, MD; Vernon M. Chinchilli, PhD; Fernando Martinez, MD; Theresa Guilbert, MD; Dave Mauger, PhD; Ian Paul, MD; Brenda Phillips, MS; Sue Boehmer, MA; James Goodwin, PhD; Tina Oliver, CCRP, CRT; D Sundström; James Schmidt, BS; Sarah Garibay, RN; Kelly Miller, BS Holly Eversoll, RN.

Equipment Committee: Wayne Morgan, MD (Chair); Gary Larsen, MD; Christine A. Sorkness, PharmD; Kevin, Hodgdon, Trisha Washington; Rick Kelley; Ryan Burton; Kelly Miller; Sarah Garibay; Holly Eversoll; Lisa Hurley; Jesus Wences; Melanie Phillips; Brenda Phillips; Loretta Doty; Richard Evans; Linda Ferrari, Jeff Davis.

Genetics Committee: Fernando D. Martinez, MD (Chair); Stanley J. Szeffler, MD; Robert F. Lemanske, Jr., MD; Vernon M. Chinchilli, PhD; David T. Mauger, PhD; Brenda Phillips, MS.

Pharmaceutical Suppliers: TEVA Respiratory, LLC, Horsham, PA, donated QVAR and placebo and albuterol.

Equipment and Materials Support: Lincoln Diagnostics donated Multi-Test II kits, Decatur, Illinois; Aerocrine, Inc. New Providence, NJ; VIASYS Healthcare GmbH, Hoechberg, Germany.